-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Biopharmaceutical company Y-mAbs Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has approved DANYELZA (naxitamab-gqgk) in association with granulocyte macrophage cluster stimulation factor (GM-CSF) for the treatment of patients with bone recurrence or refractory high-risk neuroblastoma aged 1 year and older.
DANYELZA is a humanized monoclonal antibody that targets neuroglycoside gD2, which is highly expressed in tumors and sarcoma derived from various neuroassophase layers.
in outpatients, DANYELZA was given three times a week and repeated every four weeks.
the product has been awarded the FDA's orphan drug title, breakthrough therapy title and rare pediatric disease title.
Somas Gad, Chairman and President of Y-mAbs Therapeutics, said, "Today is an important day for children with recurring/recurring high-risk neuroblastoma."
neuroblastoma is a cancer that forms in nerve cells.
it often starts with the adrenal glands, and it may also start with the nerve tissue around the spine and form a block (masses) in the neck, chest, abdominal cavity, or spine.
neuroblastoma is the most common cancer in the infant population and the third most common cancer in children.
90 per cent of neuroblastoma cases are diagnosed in children aged five and under.
。